TGFB1 and glioblastoma: Inhibition of TGF-β in hepatocellular carcinoma (HCC) and glioblastoma revealed anti-angiogenic benefit offering the rational to combine anti-TGF-β agents with anti-VEGF (Fransvea et al., 2009; Comunanza and Bussolino, 2017).